The clinical experts said that different treatment options, including Memokath 051, are available in the NHS for people with ureteric obstruction. They considered that treatments need to be offered to people on an individual basis, guided by clinical assessment of individual circumstances. Important factors to consider include the cause of the obstruction and its length and location. Clinicians should also take into account the person's preference. For people with malignant ureteric obstruction, quality of life is often the most important factor in determining what treatment will be needed. Memokath 051's advantages over some other treatments available for ureteric obstruction in the NHS are that it is a less invasive procedure with no need for hospital stay, and fewer stent replacements are needed. For people with benign ureteric obstruction, Memokath 051 is an option if they cannot have, or prefer not to have, open surgical procedures such as reconstructive surgery. The clinical experts said that Memokath 051 should not be used in people with bladder cancer or bladder stones, or in people with pelvi-ureteric junction obstruction because of an increased risk of stent migration. It concluded that careful patient selection for Memokath 051 is important when treating ureteric obstruction.